Cargando…
A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors
CPT-11 is a widely-used anti-cancer drug that is converted in vivo to its active metabolite, SN-38. In the liver, enzymes detoxify SN-38 by coupling it to a glucuronidate moiety and this inactive compound (SN-38G) is excreted into the gastrointestinal tract. In the intestine, commensal bacteria conv...
Autores principales: | Ahmad, Syed, Hughes, Mark A, Lane, Kimberly T, Redinbo, Matthew R, Yeh, Li-An, Scott, John E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106358/ https://www.ncbi.nlm.nih.gov/pubmed/21643506 http://dx.doi.org/10.2174/1875397301105010013 |
Ejemplares similares
-
The in vitro metabolism and in vivo pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652
por: Kerins, Anna, et al.
Publicado: (2022) -
Microbial β-glucuronidases drive human periodontal disease etiology
por: Lietzan, Adam D., et al.
Publicado: (2023) -
Phenoxyacetohydrazide Schiff Bases: β-Glucuronidase Inhibitors
por: Jamil, Waqas, et al.
Publicado: (2014) -
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
por: Bhatt, Aadra P., et al.
Publicado: (2020) -
Characterizing the metabolic effects of the selective inhibition of gut microbial β-glucuronidases in mice
por: Letertre, Marine P. M., et al.
Publicado: (2022)